30,012 Shares in Boston Scientific Corporation $BSX Acquired by NewEdge Wealth LLC

NewEdge Wealth LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 30,012 shares of the medical equipment provider’s stock, valued at approximately $1,281,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. Brighton Jones LLC boosted its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. FWL Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Main Street Financial Solutions LLC raised its holdings in Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after acquiring an additional 1,971 shares during the last quarter. Ieq Capital LLC lifted its stake in Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after purchasing an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its stake in Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BSX shares. Canaccord Genuity Group dropped their price target on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Wells Fargo & Company reduced their price objective on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 30th. Raymond James Financial reissued an “outperform” rating and set a $57.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Piper Sandler restated an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a report on Friday, June 12th. Finally, Citigroup cut their target price on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 194,522 shares of company stock valued at $9,385,210 over the last quarter. 0.34% of the stock is owned by company insiders.

Boston Scientific Trading Up 2.1%

Shares of BSX stock opened at $50.39 on Friday. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The firm has a market cap of $73.03 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. The company has a 50-day moving average of $46.34 and a two-hundred day moving average of $57.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the firm earned $0.75 EPS. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.